Figure 2.

Overview of the novel therapeutic strategies to overcome resistance to anti-HER2 therapies in HER2 BC (highlighted in red). The figure includes the therapies under clinical validation, including novel anti-HER2 drugs (novel TKIs, antibodies, ADCs, CAR-T cells, etc.), immunotherapies, CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors, endocrine therapy, Hsp90 and HDAC inhibitors, other RTKs inhibitors, non-receptor tyrosine kinase inhibitors, FASN inhibitors, and PARP inhibitors. Furthermore, novel approaches under preclinical validation are also pointed out, such as nanotherapy, inhibition of pro-survival autophagy, and targeting of HER2 amplicon genes (e.g., GSDMB). Icons designed with smart.servier.com and Adobe Illustrator.